甘酸通过通过肠道微生物群调节改善肠道屏障功能来改善性结肠炎
Yuwei Ye1, Abudumijiti Abulizi1, Yukun Zhang1
1State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
International journal of molecular sciences
|March 27, 2025
概括
来自Ganoderma lucidum的甘酸 (GA) 在治疗性结肠炎 (UC) 中表现有前途. GA改善了肠道屏障功能并改变了肠道微生物群,为UC患者提供了潜在的治疗策略.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,具有重大的全球健康和经济影响.
- 目前对UC的治疗需要开发新的,安全和有效的治疗药物.
研究的目的:
- 为了研究甘酸 (GA) 的预防和治疗潜力,甘酸是Ganoderma lucidum的关键成分,在硫酸 (DSS) 诱导的UC的小鼠模型中.
主要方法:
- 将GA给DSS诱导的UC小鼠,以评估其对疾病活性,结肠长度和脏指数的影响.
- 评估肠道炎症标记物和紧结蛋白表达 (ZO-1,奥克卢丁,克劳丁-1).
- 共住和便微生物种移植实验以确定肠道微生物群的作用;16S rDNA测序以分析微生物组成;Caco-2细胞模型以评估与特定代谢物的屏障功能.
主要成果:
- 在UC小鼠中,GA显著减轻了体重减轻和疾病活性指数.
- GA治疗恢复了结肠长度和指数,减少了肠道炎症,并提高了紧结蛋白的调节,增强了肠道屏障功能.
- 肠道微生物群被认为对GA的治疗作用至关重要,GA丰富了诸如Lactobacillus和Oscillospira之类的有益细菌,而特定的代谢物 (IAAld,Gln,GSH) 减少了屏障损伤.
结论:
- 甘酸在临床前模型中对性结肠炎表现出显著的改善作用.
- GA的治疗作用通过调节肠道微生物群和改善肠道屏障完整性来调节.
- GA代表了UC的潜在治疗候选者,通过肠道微生物群和相关的代谢途径起作用.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
114
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
114
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
327
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
327
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
320
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
320
01:17Drugs for Treatment of Diarrhea-Predominant IBS
131
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
131
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
323
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
323
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
103
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
103